 Predictive Oncology Inc. NASDAQ:POAI has reported its financial results for 2021, a year which saw the company strengthen its balance sheet, acquire zPREDICTA Inc, and expand its sales and business development. The Minneapolis, Minnesota-based company, which is focused on applying AI to develop personalized cancer therapies, showed earlier this year via its proof-of-concept campaign that its Patient-centric Discovery by Active Learning PeDal platform could make high-confidence predictions of drug responses on ovarian tumor samples. 